Fig. 1 · Structure

Documents & Downloads

Lapatinib (free base)

Lapatinib is a dual tyrosine kinase inhibitor which interrupts the HER2 growth receptor pathway. Lapatinib is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively. Lapatinib induces ferroptosis and autophagic cell death.

In Stock

Publications for Lapatinib (free base)

10 publications citing this product

  1. Natasa Stojanovic Guzvic, .et al. , Mol Oncol, 2024, Oct 5 PMID: 39367702
  2. Majid Momeny, .et al. , EMBO Mol Med, 2024, Jun 17 PMID: 38886591
  3. Aya Hasan Alshammari, .et al. , Biochem Pharmacol, 2022, Mar;197:114914 PMID: 35041812
  4. Adi Jacob Berger, .et al. , Nat Cancer, 2021, 2, 1055-1070 PMID: 35121883
  5. Hamzehlou S, .et al. , Eur J Pharmacol, 2019, Nov 15;863:172705 PMID: 31574259
  6. Momeny M, .et al. , Cell Oncol (Dordr), 2019, Apr 25 PMID: 31025257
  7. Tzeng SF, .et al. , FASEB J, 2018, Jun 15:fj201800687 PMID: 29906246
  8. Fujita KI, .et al. , J Pharm Sci, 2017, Sep;106(9):2632-2641 PMID: 28479358
  9. Yuki Kawasaki, .et al. , Sci Rep, 2016, 6: 31502 PMID: 27531070
  10. Tetsuya Saita, .et al. , Biol Pharm Bull. , 2015, 38(10):1652-7 PMID: 26424026

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

The deposited X-ray structure PDB 1XKK reports an EGFR kinase-domain complex with lapatinib (GW572016) at 2.40 Å resolution. The bound ligand is recorded as chemical component FMM. This is a molecular-level structural observation: the neutral chemical-component representation does not establish the starting reagent salt, free-base formulation performance, kinase potency, cellular response or tumour efficacy. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
ErbB2 IC50 9.2nM
EGFR IC50 10.8nM
ErbB4 IC50 367nM
c-Src IC50 3.5μM
C-Raf-1 IC50 >10μM
MEK IC50 >10μM
ERK IC50 >10μM
c-Fms IC50 >10μM
CDK1 IC50 >10μM
CDK2 IC50 >10μM
p38 IC50 >10μM
Tie-2 IC50 >10μM
VEGFR2 IC50 >10μM

13 targets · Scroll to view more

Cellular Effect

Cell Line Activity Value Description Reference
3T3 EC50 13 μM Antitrypanosomal activity against Trypanosoma cruzi Tulahuen amastigotes infected in rat 3T3 cells after 48 hrs by chlorophenol red-beta-D-galactopyranoside based assay [PMID: 28337329]
A2780 IC50 10.4 μM Antiproliferative activity against human A2780 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay [PMID: 31655429]
A2780 IC50 10.4 μM Antiproliferative activity against human A2780 cells after 72 hrs by MTT assay [PMID: 29684708]
A-431 IC50 > 10000 nM Inhibition of IGF1R intracellular phosphorylation in human A431 cells by ELISA [PMID: 20346655]
A-431 IC50 0.15 μM Antiproliferative activity against human A431 cells expressing EGFR/HER2 assessed as reduction in cell viability measured after 48 hrs by MTT assay [PMID: 27769671]
A-431 IC50 0.97 μM Cytotoxicity against human A431 cells overexpressing EGFR by resazurin dye reduction assay [PMID: 21080629]
A-431 IC50 104 nM Cytotoxicity against human A431 cells overexpressing HER-1 gene after 72 hrs by SRB assay [PMID: 22372864]
A-431 IC50 104 nM Cytotoxicity against human A431 cells after 72 hrs by SRB assay [PMID: 19888761]
A-431 IC50 2.6 μM Antiproliferative activity against human A431 cells overexpressing EGFR after 72 hrs by MTT assay [PMID: 22595177]
A-431 IC50 2.62 μM Cytotoxicity against human A431 cells overexpressing EGFR after 72 hrs by MTT assay [PMID: 22182581]
A-431 IC50 2.66 μM Antiproliferative activity against human A431 cells after 72 hrs by MTT assay [PMID: 30508379]
A-431 IC50 3.59 μM Antiproliferative activity against human A431 cells overexpressing EGFR assessed as cell growth inhibition measured after 72 hrs by MTT assay [PMID: 32139324]
A-431 IC50 4.8 μM Antiproliferative activity against human A431 cells incubated for 72 hrs by MTT assay [PMID: 31202990]
A-431 IC50 4.8 μM Antiproliferative activity against human A431 cells harboring wild type EGFR after 72 hrs by MTT assay [PMID: 29421573]
A-431 IC50 4.8 μM Antiproliferative activity against human A431 cells harboring wild type EGFR after 72 hrs by MTT assay [PMID: 28711703]
A-431 IC50 4.8 μM Antiproliferative activity against human A-431 cells assessed as cell growth inhibition by MTT assay [PMID: 32739648]
A-431 IC50 52 nM Inhibition of EGFR intracellular phosphorylation in human A431 cells by ELISA [PMID: 20346655]
A-431 IC50 643.1 nM Cytotoxicity against human A431 cells assessed as inhibition of cell growth after 72 hrs by sulforhodamine B assay [PMID: 25305330]
A549 IC50 0.51 μM Cytotoxicity against human A549 cells expressing EGFR and KRAS mutant assessed as reduction in cell viability measured after 48 hrs by MTT assay [PMID: 27769671]
A549 IC50 11 μM Antiproliferative activity against human A549 cells overexpressing EGFR assessed as reduction in cell viability incubated for 72 hrs by MTT assay [PMID: 31125894]

20 records · Scroll to view more

In Vitro Studies

Deposited EGFR–lapatinib crystal complex

Biochemical assay · Human EGFR kinase-domain crystallographic complex, PDB 1XKK; a purified-protein structural experiment, not a human or animal treatment study. [1]

The deposited X-ray structure PDB 1XKK reports an EGFR kinase-domain complex with lapatinib (GW572016) at 2.40 Å resolution. The bound ligand is recorded as chemical component FMM. This is a molecular-level structural observation: the neutral chemical-component representation does not establish the starting reagent salt, free-base formulation performance, kinase potency, cellular response or tumour efficacy.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Reported high-resolution limit of the deposited crystal diffraction modelX-ray resolution 2.40 Å[1]

Literature-Reported Treatment Conditions

Method
X-ray diffraction of an EGFR kinase-domain complex containing modeled FMM ligand. No assay dosing schedule is adopted.
Reported limits
The retrieved deposit/CCD identity records do not establish the starting reagent salt, supplier or lot. Journal full methods were not retrieved. No treatment potency or dose is transferred from this structure.
Methods and source locations

Compound reported in the paper: Lapatinib; Compound label in the paper: GW572016; PDB chemical component FMM

Compound-level EGFR complex observation only. A neutral CCD representation does not demonstrate the experimental protonation state or starting free-base material. No salt equivalence, potency/dose transfer or product-lot validation is asserted.

PDB 1XKK v1.3: _struct.title; _entity (EGFR kinase domain); _pdbx_entity_nonpoly (FMM); _atom_site FMM rows; _exptl.method; _refine.ls_d_res_high; _citation and _database_2

Reported high-resolution limit of the deposited crystal diffraction model: X-ray diffraction; deposited _refine.ls_d_res_high. Depositor Rwork 0.209 and Rfree 0.255 were checked as model context, not independent re-refinement. — PDB 1XKK v1.3 mmCIF: _exptl.method; _refine.ls_d_res_high, _refine.ls_R_factor_R_work and _refine.ls_R_factor_R_free

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 231277-92-2
Formula C29H26ClFN4O4S
Molecular Weight 581.1
SMILES
CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 99 mg/mL (170.37 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
9 mg/mL
Vehicle
2% DMSO+30% PEG 300+5% Tween 80+ddH2O

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Wood, E.R., Truesdale, A.T., McDonald, O.B., et al. EGFR kinase domain complexed with a quinazoline inhibitor- GW572016 Protein Data Bank (2004). DOI: 10.2210/pdb1xkk/pdb Source material

Publications

10 publications citing this product

  1. Natasa Stojanovic Guzvic, .et al. , Mol Oncol, 2024, Oct 5 PMID: 39367702
  2. Majid Momeny, .et al. , EMBO Mol Med, 2024, Jun 17 PMID: 38886591
  3. Aya Hasan Alshammari, .et al. , Biochem Pharmacol, 2022, Mar;197:114914 PMID: 35041812
  4. Adi Jacob Berger, .et al. , Nat Cancer, 2021, 2, 1055-1070 PMID: 35121883
  5. Hamzehlou S, .et al. , Eur J Pharmacol, 2019, Nov 15;863:172705 PMID: 31574259
  6. Momeny M, .et al. , Cell Oncol (Dordr), 2019, Apr 25 PMID: 31025257
  7. Tzeng SF, .et al. , FASEB J, 2018, Jun 15:fj201800687 PMID: 29906246
  8. Fujita KI, .et al. , J Pharm Sci, 2017, Sep;106(9):2632-2641 PMID: 28479358
  9. Yuki Kawasaki, .et al. , Sci Rep, 2016, 6: 31502 PMID: 27531070
  10. Tetsuya Saita, .et al. , Biol Pharm Bull. , 2015, 38(10):1652-7 PMID: 26424026

Added to your cart

View Cart Checkout
Loading...